China Biologic Products to Ring NASDAQ Opening Bell
December 10 2009 - 8:00AM
PR Newswire (US)
TAI'AN, China, Dec. 10 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (NASDAQ:CBPO) ("China Biologic," or the
"Company"), one of the leading plasma-based biopharmaceutical
companies in China, today announced that the Company's senior
management team will ring the opening bell at the NASDAQ MarketSite
in New York City at 9:30 a.m. ET on Tuesday, December 15, 2009.
China Biologic's common stock began trading on the NASDAQ Global
Market on December 2, 2009, under the ticker symbol "CBPO." "We are
honored to ring the NASDAQ opening bell to celebrate our listing on
one of the most prestigious equity markets in the world," said Mr.
Chao Ming Zhao, China Biologic's Chief Executive Officer. "We would
like to thank our shareholders, dedicated employees, board of
directors, management team, and all other parties who have
contributed to our success to date." A live webcast of the NASDAQ
Opening Bell (starting from 9:20 a.m. ET) will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx About China
Biologic Products, Inc. China Biologic Products, Inc. (the
"Company"), through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin
Biologic Technologies Co., Ltd, and its equity investment in Xi'an
Huitian Blood Products Co., Ltd., is currently the largest
non-state-owned plasma-based biopharmaceutical company in China.
The Company is a fully integrated biologic products company with
plasma collection, production and manufacturing, research and
development, and commercial operations. The Company's plasma-based
biopharmaceutical products are irreplaceable during medical
emergencies, and are used for the prevention and treatment of
various diseases. The Company sells its products to hospitals and
other healthcare facilities in China. For more information please
visit the Company's website http://www.chinabiologic.com/ . Safe
Harbor Statement This release may contain certain "forward-looking
statements" relating to the business of China Biologic Products,
Inc. and its subsidiary companies. All statements, other than
statements of historical fact included herein are "forward-looking
statements," including statements regarding: the significance of
the Company's listing on the NASDAQ Global Market; the ability of
the Company to achieve its commercial objectives; the business
strategy, plans and objectives of the Company and its subsidiaries;
and any other statements of non-historical information. These
forward-looking statements are often identified by the use of
forward-looking terminology such as "believes," "expects" or
similar expressions, and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they
do involve assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that
are filed with the Securities and Exchange Commission and available
on its website (http://www.sec.gov/ ). All forward-looking
statements attributable to the Company or persons acting on its
behalf are expressly qualified in their entirety by these factors.
Other than as required under the securities laws, the Company does
not assume a duty to update these forward-looking statements. For
more information, please contact: Company Contact: Mr. Y. Tristan
Kuo Chief Financial Officer China Biologic Products, Inc. Tel:
+86-538-6202206 Email: Web: http://www.chinabiologic.com/ Investor
Relations Contact: CCG Investor Relations Mr. Athan Dounis, Account
Manager Tel: +1-646-213-1916 Email: Mr. Crocker Coulson, President
Tel: +1-646-213-1915 Email: Web: http://www.ccgirasia.com/
DATASOURCE: China Biologic Products, Inc. CONTACT: Y. Tristan Kuo,
Chief Financial Officer of China Biologic Products, Inc.,
+86-538-6202206, ; Investor Relations Contact: Athan Dounis,
Account Manager at CCG Investor Relations, +1-646-213-1916, , or
Crocker Coulson, President, +1-646-213-1915, Web site:
http://www.chinabiologic.com/ http://www.ccgirasia.com/
http://www.nasdaq.com/about/marketsitetowervideo.asx
Copyright